Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Autolus Therapeutics plc - American Depositary Shares (AUTL)
Last autolus therapeutics plc - american depositary shares earnings: 11/7 07:06 am
Check Earnings Report
US:NASDAQ Investor Relations:
autolus.com/investor-relations
Company Research
Source: Yahoo! Finance
Total Net Operating Expenses: $67.9 million for Q3 2024, up from $42.9 million in Q3 2023. Research and Development Expenses: Increased to $40.3 million in Q3 2024 from $32.3 million in Q3 2023. General and Administrative Expenses: Increased to $27.3 million in Q3 2024 from $10.6 million in Q3 2023. Net Loss: $82.1 million for Q3 2024, compared to $45.8 million in Q3 2023. Product Pricing: AUCATZYL priced at $525,000. Milestone Payments: $30 million from Blackstone and GBP10 million regulatory milestone payment due in Q4 2024. Warning! GuruFocus has detected 3 Warning Signs with AUTL. Release Date: November 12, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Autolus Therapeutics PLC ( NASDAQ:AUTL ) received FDA approval for AUCATZYL, marking a significant milestone for the company and providing a new treatment option for patients with relapsed or refractory ALL. The company has successfully onboarded 30 cent
Show less
Read more
Impact Snapshot
Event Time:
AUTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUTL alerts
High impacting Autolus Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AUTL
News
- T-cell Malignancies Market Dynamics: Key Insights on Acute Lymphocytic Leukemia, Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Adult T-cell Leukemia/Lymphoma | DelveInsight [Yahoo! Finance]Yahoo! Finance
- T-cell Malignancies Market Dynamics: Key Insights on Acute Lymphocytic Leukemia, Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Adult T-cell Leukemia/Lymphoma | DelveInsightPR Newswire
- T-cell Malignancies Market Dynamics: Key Insights on Acute Lymphocytic Leukemia, Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Adult T-cell Leukemia/Lymphoma | DelveInsightPR Newswire
- Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 [Yahoo! Finance]Yahoo! Finance
- Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024GlobeNewswire
AUTL
Earnings
- 11/12/24 - Miss
AUTL
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form S-8
- 11/14/24 - Form SC
- AUTL's page on the SEC website